MedTrace Logo

Acute Effects of Jägermeister With Energy Drinks (Jägermbomb)

NCT07588022 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-05-14

No results posted yet for this study

Summary

The main objective of this study is to compare the acute effects of drinking Jägerbombs with drinking alcohol alone during a binge-drinking episode, which involves consuming a large amount of alcohol in a short period of time to become intoxicated. Secondary objectives are to assess whether Jägerbombs produce prototypical alcohol effects, increase stimulation and rewarding effects, affect coordination, time reaction and vision, change stress-related hormone responses, and cause hangover symptoms.

Conditions

  • Alcohol Drinking
  • Healthy Adult Participants
  • Binge Alcohol Consumption
  • Energy Drinks

Interventions

DIETARY_SUPPLEMENT

Jägermeister and Energy Drink (Jägerbomb)

Multiple oral dose of Jägermeister mixed with ED

DIETARY_SUPPLEMENT

Jägermeister and Energy Drink Placebo

Multiple oral dose of Jägermeister mixed with a placebo of ED (non-caffeinated soft drink)

DIETARY_SUPPLEMENT

Alcohol Placebo and Energy Drink Placebo

Multiple oral dose of alcohol placebo (water) mixed with ED placebo (non-caffeinated soft drink)

Sponsors & Collaborators

  • Plan Nacional sobre Drogas

    collaborator UNKNOWN

  • Fundació Institut Germans Trias i Pujol

    lead OTHER

Principal Investigators

  • Clara Pérez Mañá, MD, PhD · Hospital Universitari Germans Trias i Pujol-IGTP

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-02-18
Primary Completion
2027-03-31
Completion
2027-06-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07588022 on ClinicalTrials.gov